Novo Nordisk announced that its leading diabetes medication, Ozempic® (semaglutide), has received a positive recommendation in the EU for an updated label to include peripheral arterial disease.
Novo Nordisk
Novo Nordisk has announced compelling results from its phase 3b STEP UP clinical trial, demonstrating that a higher 7.2 mg dose of its weight-loss medication, Wegovy® (semaglutide), led to a significant average weight loss of 21% in adults with obesity.
Novo Nordisk keeps pushing the boundaries of obesity innovation by revealing the whole Phase 3 REDEFINE 1 and 2 trial data, which shed light on CagriSema’s revolutionary potential.
The results are based on the SURMOUNT-5 Phase 3b open-label clinical trial, in which the two incretin-based drugs were directly compared over a 72-week duration.
Novo Nordisk presented the full results of STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial that looked at the effects of once-weekly injectable Ozempic®.
CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
